Sign up

Casdin Capital, LLC

$2.0B assets · 43 holdings · Q2 2026 · Filed 14 AUG 2026

About Casdin Capital, LLC’s 13F portfolio

Casdin Capital, LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Casdin Capital, LLC reported $2.0B across 43 US-listed positions (). Its largest position is REVOLUTION MEDICINES INC (RVMD) at 24% of the reported book, and its ten biggest holdings make up 77% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.

$2.0B
Assets (13F)
#1,490
of 8,839 by size
43
Holdings
77%
Top-10 weight
15
Buys
6
Sells
Top holdings · Q2 2026
43 total
#StockPrice% of portfolioSharesValue
1
NASDAQ: RVMD
REVOLUTION MEDICINES INC
$159.43
−0.24%
24%
2.6M$482.7M
2
NASDAQ: RLAY
RELAY THERAPEUTICS INC
$15.91
−3.63%
15%
16.0M$300.0M
3
NASDAQ: WGS
GENEDX HOLDINGS CORP
$49.24
−5.23%
13%
3.7M$254.5M
4
NASDAQ: BLFS
BIOLIFE SOLUTIONS INC
$38.61
0.00%
6.6%
4.7M$131.5M
5
NASDAQ: ILMN
ILLUMINA INC
$200.66
−4.45%
4.7%
530K$93.2M
6
NASDAQ: LAB
STANDARD BIOTOOLS INC
$0.61
+7.67%
3.7%
88.8M$73.0M
7
NASDAQ: GPCR
STRUCTURE THERAPEUTICS INC
$17.12
−1.38%
3.2%
1.2M$63.1M
8
NASDAQ: DNLI
DENALI THERAPEUTICS INC
$18.20
−1.09%
2.6%
2.0M$52.6M
9
NASDAQ: NGNE
NEUROGENE INC
$22.93
−0.91%
2.4%
1.5M$48.6M
10
NASDAQ: BEAM
BEAM THERAPEUTICS INC
$20.94
−0.33%
2.3%
1.4M$46.3M
11
NASDAQ: TXG
10X GENOMICS INC
$57.38
+0.54%
2.0%
1.1M$40.3M
12
NASDAQ: SRRK
SCHOLAR ROCK HLDG CORP
$50.37
+4.94%
1.8%
665K$36.6M
13
NASDAQ: PSNL
PERSONALIS INC
$14.72
−1.74%
1.7%
2.5M$34.2M
14
NASDAQ: GRAL
GRAIL INC
$104.84
+2.68%
1.6%
480K$32.8M
15
NASDAQ: GH
GUARDANT HEALTH INC
$145.59
+0.31%
1.4%
185K$27.8M
16
NASDAQ: MAZE
MAZE THERAPEUTICS INC
$32.43
+3.94%
1.3%
844K$25.2M
17
NYSE: HIMS
HIMS & HERS HEALTH INC
$16.02
−6.04%
1.2%
700K$24.3M
18
NASDAQ: ALNY
ALNYLAM PHARMACEUTICALS INC
$147.82
−1.06%
1.1%
75K$22.6M
19
NASDAQ: TSHA
TAYSHA GENE THERAPIES INC
$3.77
−5.51%
1.1%
3.3M$22.1M
20
NASDAQ: AGMB
AGOMAB THERAPEUTICS NV
—
—
1.0%
1.6M$20.1M
21
NASDAQ: SEPN
SEPTERNA INC
$39.20
−0.63%
0.9%
553K$18.5M
22
NASDAQ: PBLS
PARABILIS MEDICINES INC
—
—
0.9%
646K$17.7M
23
NASDAQ: SION
SIONNA THERAPEUTICS INC
$2.97
+0.00%
0.9%
400K$17.6M
24
NASDAQ: VCYT
VERACYTE INC
$25.04
−2.07%
0.8%
276K$16.2M
25
NASDAQ: ANL
ADLAI NORTYE LTD
$9.06
+3.66%
0.7%
1.3M$14.4M

Showing 1–25 of 43 positions on this page reported in this 13F.

Sector allocation
  • Healthcare98%
Recent activity · vs 2026-03-31
Bought15
  • AddedRLAYRELAY THERAPEUTICS INC+11.2%$300.0M
  • AddedWGSGENEDX HOLDINGS CORP+23.3%$254.5M
  • AddedDNLIDENALI THERAPEUTICS INC+11.1%$52.6M
  • AddedNGNENEUROGENE INC+8.8%$48.6M
  • AddedSRRKSCHOLAR ROCK HLDG CORP+90.0%$36.6M
  • AddedPSNLPERSONALIS INC+59.4%$34.2M
  • AddedGRALGRAIL INC+109%$32.8M
  • AddedMAZEMAZE THERAPEUTICS INC+11.2%$25.2M
  • NewPBLSPARABILIS MEDICINES INC—$17.7M
  • NewSIONSIONNA THERAPEUTICS INC—$17.6M
Sold6
  • ReducedBLFSBIOLIFE SOLUTIONS INC−21.9%$131.5M
  • ReducedTXG10X GENOMICS INC−53.8%$40.3M
  • ReducedGHGUARDANT HEALTH INC−41.3%$27.8M
  • SoldQGENQIAGEN NV−100%—
  • SoldMLTXMOONLAKE IMMUNOTHERAPEUTICS−100%—
  • SoldTEMTEMPUS AI INC−100%—
5%+ Beneficial Ownership Stakes · 2 passive (13G)

Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.

#StockType% of classSharesFiled
1
BLFS
BIOLIFE SOLUTIONS INC
13G9.7% · 2 classes4.8MFiled 04 JUN 2026
2
RLAY
Relay Therapeutics, Inc.
13G7.5%13.0MFiled 17 FEB 2026

Showing all 2 disclosed stakes.

Reading Casdin Capital, LLC’s 13F portfolio

Casdin Capital, LLC’s $2.0B 13F book is spread across 43 reported positions and is highly concentrated — its ten largest positions alone are 77% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are RVMD, RLAY, WGS, BLFS and ILMN, led by REVOLUTION MEDICINES INC (RVMD) at 24% of the portfolio. The heaviest sector exposure is Healthcare (98%).

What Casdin Capital, LLC changed last quarter

Between 2026-03-31 and Q2 2026, Casdin Capital, LLC was a net buyer: it opened 6 new positions and added to 9 more, while trimming 3 and closing 3 outright. Against a 43-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was RELAY THERAPEUTICS INC (RLAY), and its biggest reduction was BIOLIFE SOLUTIONS INC (BLFS).

What a 13F does and doesn’t reveal

A 13F captures only Casdin Capital, LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Casdin Capital, LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.

Frequently asked questions

What is an SEC 13F filing?

A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Casdin Capital, LLC's profile on this page is built directly from those filings.

How current is the 13F data on Casdin Capital, LLC's page?

It reflects Casdin Capital, LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Casdin Capital, LLC files its next quarterly report, this page refreshes automatically.

Can I see Casdin Capital, LLC's complete list of holdings?

This page highlights Casdin Capital, LLC's largest positions rather than all 43 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Casdin Capital, LLC's filings.

Does a 13F show everything Casdin Capital, LLC owns?

No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Casdin Capital, LLC's book rather than its full strategy or total assets.

Is 13F data investment advice?

No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Casdin Capital, LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.

Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.